AbbVie is planting its biggest single-site bet in Durham. The drugmaker’s $1.4 billion manufacturing campus, announced this spring and moving into construction through 2026, spreads across 185 acres and marks the company’s first major operation in North Carolina. It’s AbbVie’s largest investment in one location to date.
Project Scope
Phase one centers on small-volume parenteral drug product manufacturing, the sterile injectable and infusion products that carry AbbVie’s immunology, neuroscience and oncology portfolios. The campus pairs those production lines with next-generation laboratories, a warehouse and administrative offices, and the company says it will fold artificial intelligence into both manufacturing and lab operations. Sterile fill-finish work sets a high bar for the builders: cleanroom classifications, tight vibration and humidity control, and validation protocols that govern how every pipe, weld and air handler gets documented before a single dose is made. Construction is expected to run into 2028, with roughly 2,000 building-trades jobs on site during the peak.
Why It Matters
Pharmaceutical reshoring has become one of the steadier corners of the U.S. factory boom, and North Carolina’s Research Triangle keeps winning these campuses on the strength of its talent pipeline and existing life-sciences cluster. AbbVie plans to hire 734 engineers, scientists, operators and technicians once the plant runs, permanent jobs that tend to anchor suppliers and contractors around them for years. For the region’s builders, a fill-finish campus is the kind of high-spec, long-duration work that rewards firms with real pharma experience and punishes those learning on the job.
Project Team & Details
| Developer | AbbVie |
|---|
| Owner / Client | AbbVie |
|---|
| Status | Under Construction |
|---|
| Funding Source | Private |
|---|
